Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Filings indexed 492 across all filing types
Latest filing 2026-03-30 Annual Report
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
Annual Report
2026-03-30 English
8-K/A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
Regulatory Filings
2026-03-26 English
8-K - ACTINIUM PHARMACEUTICALS, INC. (0001388320) (Filer)
Regulatory Filings
2026-02-13 English
CURRENT REPORT
Regulatory Filings
2025-11-26 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2025
2025-11-14 English
ARS
Annual Report
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.